

Inovio Biomedical

[View the current Inovio Biomedical Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/23422-Inovio+Biomedical.html)

(<http://www.bioportfolio.com/bi corporate/23422-Inovio+Biomedical.html>)

Contact Details:

11494 Sorrento Valley Rd.
San Diego
California
92121-1318
United States of America

Tel: 858-597-6006 or 877-446-6846 (877-4-INOVIO)

Fax: 858-597-0451

Email: new.products@inovio.com

Inovio Biomedical Corporation (AMEX: INO) is a leader in cancer and other medical therapies using electroporation-enabled delivery of useful biopharmaceuticals

Inovio Biomedical Corporation (AMEX: INO) is a late stage biomedical company developing novel therapies enabled by electroporation, with a focus on addressing critical unmet treatment needs in oncology. Clinical results validate its local cancer therapy's ability to preserve healthy tissue while selectively killing cancer cells in solid tumors. Compared to surgery, this treatment is simpler, superior in its ability to preserve tissue structure and function (providing quality of life benefits), and lower cost. Inovio's non-viral delivery platform enabled the first-ever clinical study to deliver a gene in humans using electroporation. With the validation of promising pre-clinical data and licensing agreements with Merck and Vical, the company's technology may be instrumental in achieving the potential of important therapeutic genes and DNA vaccines.

Recent Publications by Inovio Biomedical:



- [Electroporation of cytokines for cancer gene therapy.](#)
INTRODUCTION: Circulating tumor cells (CTCs) are detectable in most cancer... 14th October, 2009
Inovio Biomedical Corporation, Blue Bell, PA, USA.- *Cancer Biol Ther.* 2009 Nov 15;8(22).
- [Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma.](#)
Immunotherapy of cancer offers great promise, however translation into... 30th September, 2009
Department of Research and Development, Inovio Biomedical Corporation, San- *Oncol Rep.* 2009 Nov;22(5):1197-203.
- [Applicator and electrode design for in vivo DNA delivery by electroporation.](#)
As in vivo electroporation advances from the preclinical phase to clinical... 6th June, 2008
Inovio Biomedical Corp., San Diego, CA, USA.- *Methods Mol Biol.* 2008;423:35-59. ([DOI Direct Link](#))

- [\[DNA--the future in vaccine technology?\]](#)

*DNA vaccines represent a new and promising technology that uses DNA to...*9th December, 2006
 Inovio Biomedical Corporation, 11494 Sorrento Valley Road, San Diego, CA,- Tidsskr Nor Laegeforen.
 2006 Nov 16;126(22):2964-8.

Press Releases on Inovio Biomedical:

Reportlinker Adds Cholesterol and Other Cardiovascular Testing - Trends & Opportunities Worldwide	25th November, 2009	Reportlinker	<i>NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cholesterol and Other Cardiovascular Testing - Trends & Opportunities</i>
Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada	24th November, 2009		<i>BOZEN, Italy, November 24 /PRNewswire/ -- Health Robotics today announced that it has formed a new Canadian joint venture with a group of selected investors. This recently formed Toronto-based company</i>
Reportlinker Adds Microtomes/Cryostats & Automated Stainers - Global Market Trends	23rd November, 2009	Reportlinker	<i>NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Microtomes/Cryostats & Automated Stainers - Global Market Trends http:</i>
Four Senior Executives Join Orexigen(R) Therapeutics Management Team	23rd November, 2009	Orexigen Therapeutics, Inc.	<i>SAN DIEGO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that four senior executives have joined the organization, strengthening the management</i>
Inimex Announces Appointment of New CEO	23rd November, 2009	Inimex Pharmaceuticals Inc.	<i>BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO. Abrams brings more than 25 years of drug</i>

- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
Stock Junction: Nov 21 2009 7:07AM Matching: inovio biomedical
- [News and FDA Updates for Covidien \(NYSE:COV\), Antigenics \(NASDAQ:AGEN\), Inovio \(NYSE:INO\)](#)
Los Angeles Chronicle: Nov 21 2009 8:33PM Matching: inovio biomedical
- [Inovio Biomedical Corporation \(INO\) Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Aga](#)
BioSpace: Nov 21 2009 12:39AM Matching: inovio biomedical
- [Today's Big Gainers: INO, SRLS, KIRK, GFF](#)
Individual.com: Nov 21 2009 4:53AM Matching: inovio biomedical
- [Inovio Biomedical to Present at Global Vaccine Conferences](#)
Pharma Live: Nov 20 2009 9:10PM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
StockHouse USA: Nov 20 2009 11:12AM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
Pharma Live: Nov 20 2009 2:27PM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
Reuters: Nov 20 2009 11:57AM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
Business Wire: Nov 20 2009 11:06AM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies](#)
Business Wire UK: Nov 20 2009 11:15AM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
Street Insider: Nov 20 2009 11:05AM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly](#)
Business Wire via MSN Money: Nov 20 2009 11:23AM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
Globe Investor: Nov 20 2009 11:19AM Matching: inovio biomedical
- [Inovio Biomedical announces positive test results of its consensus influenza vaccines](#)
News-Medical.Net: Nov 20 2009 12:40PM Matching: inovio biomedical
- [Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seas](#)
Genetic Engineering News: Nov 20 2009 11:48AM Matching: inovio biomedical



- [Medpulsar Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

